|
SX-GIP34
is a novel oncology therapeutic lead compound that has shown preliminary
in vivo activity against metastatic spread of breast and prostate
tumors (US Patents 5,674,842 and 5,707,963).
SX-ARPC
is a novel family of compounds that have demonstrated in vitro
ability to down regulate the AR pathway. Optimized version of these
compounds have potential as a novel therapeutic for Prostate Cancer.
SX-METF
is an novel modulator of the tumor microenvironment. This compound
has demonstrated in vitro regulatory activity for dissociation,
migration, cell adhesion, invasion and proliferation (US and International
Patents Pending).
SX-RDS1
is a novel DNA Repair Inhibitor discovered to enhance the effectiveness
of radiation therapy in a non-toxic manner. This compound is designed
to dramatically reduce the frequency and dose of radiation therapy
through a unique mechanism of action which gently disables cellular
DNA repair mechanisms without interfering with p53 pathways.
SX-PCK9
is a novel set of compounds discovered that have proven in vitro
to antagonize the interaction between PCSK9 and LDLR for the treatment
of hypercholesterolemia. The program has develeoped compounds against
both LDLR and the PCSK9 proteins.
SX-HIV1 is
a discovery stage retroviral integrase inhibitor family to prohibit
the multimerization of the highly conserved integrase enzyme used
by many human retroviruses including HIV. This multimerization process
is critical to the integration of viral genetic material with the
DNA of the infected host cell.
|
